Pre-market Movers: 2seventy bio, Sonoma Pharmaceuticals, Tenon Medical, Arvinas, NET Power Inc. | LONDON (dpa-AFX) - The following are some of the stocks making big moves in Tuesday's pre-market trading (as of 09.00 A.M. ET).In the Green 2seventy bio, Inc. (TSVT) is up over 76% at $4.93.
Sonoma... ► Artikel lesen |
Sonoma Pharmaceuticals, Inc.: Sonoma Pharmaceuticals Secures Extensive U.K. Regulatory Clearances of Key Wound Care and Dermatology Products by the Medicines & Healthcare Products Regulatory Agency | BOULDER, CO / ACCESS Newswire / March 10, 2025 / Sonoma Pharmaceuticals, Inc. (Nasdaq:SNOA), a global healthcare leader developing and producing patented Microcyn® technology based stabilized hypochlorous... ► Artikel lesen |
Sonoma Pharmaceuticals, Inc.: Sonoma Pharmaceuticals to Exhibit at 2025 American Academy of Dermatology Annual Meeting in Orlando | BOULDER, CO / ACCESS Newswire / February 25, 2025 / Sonoma Pharmaceuticals, Inc. (Nasdaq:SNOA), a global healthcare leader developing and producing patented Microcyn® technology based stabilized hypochlorous... ► Artikel lesen |
Jaguar Health, Inc.: Jaguar Health Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635 | SAN FRANCISCO, CALIFORNIA / ACCESS Newswire / April 4, 2025 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today announced that, effective April 3, 2025, the Company granted 3,600 restricted... ► Artikel lesen |
Jaguar Health, Inc.: Jaguar Health Announces Closing of Bridge Financing Priced At-The-Market Under Nasdaq Rules | SAN FRANCISCO, CALIFORNIA / ACCESS Newswire / April 1, 2025 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or "the Company"), today announced the closing of its previously announced private placement.Jaguar's... ► Artikel lesen |
Jaguar Health, Inc.: Jaguar Health Reports 2024 Financials: 2024 Net Revenue Up Approximately 20% Over 2023 | The total net revenue for the year ended December 31, 2024 of approximately $11.7 million for prescription and non-prescription products, including license revenue, increased approximately 20% versus... ► Artikel lesen |
Windtree Therapeutics Regains Compliance with Nasdaq Listing Rules | WARRINGTON, Pa., March 24, 2025 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. ("Windtree" or the "Company") (NasdaqCM: WINT), a biotechnology company focused on becoming a revenue generating biotech... ► Artikel lesen |
Windtree Therapeutics: Windtree Announces Istaroxime Notice of Allowance from the U.S. Patent and Trademark Office for Acute Heart Failure | WARRINGTON, Pa., March 04, 2025 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. ("Windtree" or the "Company") (NasdaqCM: WINT), a biotechnology company focused on advancing early and late-stage innovative... ► Artikel lesen |
Windtree Therapeutics, Inc. Announces Reverse Stock Split | WARRINGTON, Pa., Feb. 18, 2025 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (NasdaqCM: WINT) ("Windtree" or the "Company"), a biotechnology company focused on advancing early and late-stage innovative... ► Artikel lesen |